Stock Ratings | Ascendiant Capital maintains a "Buy" rating on NextTrip, Inc.(NTRP), raising its price target to $7.5, implying a 234.82% upside; Goldman Sachs raises Micron Technology(MU) price target to $900
NextTrip NTRP | 0.00 | |
Zevra ZVRA | 0.00 | |
Inhibikase IKT | 0.00 | |
Synergy CHC SNYR | 0.00 | |
Tyra Biosciences TYRA | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Ascendiant Capital: Maintains its "Buy" rating on NextTrip ( NextTrip(NTRP.US) ), raising its price target from $7 to $7.50
Maxim Group maintains its "buy" rating on Zevra Therapeutics ( Zevra(ZVRA.US) ), raising its price target from $25 to $35.
Guggenheim: Maintaining a "buy" rating on Zevra Therapeutics ( Zevra(ZVRA.US) ), while raising the price target from $25 to $29.
Oppenheimer: Initial rating for Inhibikase Therapeutics ( Inhibikase(IKT.US) ) at "outperforms the market", with a price target of $5.
Ascendiant Capital: Maintains its "buy" rating on Synergy CHC Corp. ( Synergy CHC(SNYR.US) ), while lowering its price target from $5.50 to $3.75.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| NextTrip(NTRP.US) | to lift | $7.5 | $2.24 | 234.82% | Ascendiant Capital |
| Zevra(ZVRA.US) | to lift | $35.0 | $13.5 | 159.26% | Maxim Group |
| Zevra(ZVRA.US) | to lift | $29.0 | $13.5 | 114.81% | Guggenheim |
| Tyra Biosciences(TYRA.US) | to lift | $42.0 | $25.42 | 65.22% | B of A Securities |
| Celldex Therapeutics, Inc.(CLDX.US) | to lift | $45.0 | $29.35 | 53.32% | UBS |
| Inhibikase(IKT.US) | Initial classification | $5.0 | $1.66 | 201.2% | Oppenheimer |
| Synergy CHC(SNYR.US) | cut | $3.75 | $0.187 | 1905.35% | Ascendiant Capital |
| Banzai(BNZI.US) | cut | $42.0 | $3.21 | 1208.41% | Ascendiant Capital |
| SurgePays(SURG.US) | cut | $3.5 | $0.4585 | 663.36% | Ascendiant Capital |
| Zillow Group A(ZG.US) | cut | $70.0 | $34.1 | 105.28% | RBC Capital |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
UBS: Maintaining a "buy" rating on Applied Materials ( Applied Materials(AMAT.US) ) stock, while raising the price target from $515 to $570.
Morgan Stanley: Maintaining a "Market-Similar Weight" rating for Amgen Amgen(AMGN.US) ), while raising the price target from $332 to $340.
CIBC: Maintaining Datadog's ( Datadog(DDOG.US) ) rating at "Outperforming the Market," while raising the price target from $250 to $280.
Cantor Fitzgerald: Maintaining an "overweight" rating on KLA Corporation ( KLA(KLAC.US) ), while raising the price target from $2,000 to $2,500.
Cantor Fitzgerald: Maintaining an "overweight" rating on Lam Research Lam Research(LRCX.US) stock, while raising the price target from $320 to $425.
Goldman Sachs: Maintaining a "neutral" rating on Micron Technology Micron Technology(MU.US) stock, while raising its price target from $400 to $900.
First Coverage
HC Wainwright & Co.: AnaptysBio ( AnaptysBio(ANAB.US) ) has a preliminary "buy" rating on its stock, with a target price of $95.
JP Morgan: Bel Fuse ( Bel Fuse B(BELFB.US) ) initial rating at "overweight", with a price target of $370.
Bernstein: Initial rating for Honeywell ( Honeywell(HON.US) ) stock at "Market Match", with a target price of $233.
Bernstein: Initial rating for 3M ( 3M(MMM.US) ) stock at "underperforming," with a price target of $131.
Bernstein: Initial rating for Vertiv Holdings ( VERTIV HOLDINGS LLC(VRT.US) ) stock at "outperform", with a price target of $416.
reduction
Citigroup: Maintaining a "neutral" rating on Lululemon stock ( Lululemon Athletica(LULU.US) ), while lowering the price target from $185 to $130.
Barclays: Maintaining an "overweight" rating on McKesson Corporation ( McKesson(MCK.US) , while lowering its price target from $1,050 to $925.
RBC Capital: Downgraded Nike ( NIKE(NKE.US) ) stock to "sector-matched," lowering its price target from $70 to $50.
Evercore ISI Group: Maintaining its "Outperform Market" rating for Schlumberger ( SLB(SLB.US) ), while lowering its price target from $64 to $63.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk warning:
Investing involves risk, and securities prices can rise or fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.